Notably, the p38 MAPK inhibitor (SB203580) significantly decreased the protein expression levels of CD44 in U251 and SHG44 cells with inhibition of p38 phosphorylation (Figure 10H), indicating that p38 MAPK was the upstream that governed the CD44 levels in glioma cells. Here, CD44 is linked to central nervous system cancer.